Kiran Mazumdar-Shaw names niece Claire as future Biocon leader, no timeline yet

Biocon founder Kiran Mazumdar-Shaw has identified her niece Claire Mazumdar as successor, setting in motion a leadership transition at the country’s largest biotechnology firm.

Mazumdar-Shaw, 73, said no timeline has been fixed but Claire Mazumdar, currently chief executive of Bicara Therapeutics, is expected to join in the foreseeable future.

“I am the sole owner of Biocon, and I need to make sure that I put it in good hands,” Mazumdar-Shaw told Fortune India, adding that her niece had demonstrated the ability to run a company.

In a post on X, the billionaire entrepreneur said the transition would take place “at the right time” and that she’s “not planning to hang up my boots just yet!!”

Mazumdar-Shaw founded the company over four decades ago, building it into a global biosimilars player. She has no children; her late husband, John Shaw, had served as vice chairman of the group.

Claire Mazumdar, 37, brings a scientific and business background, with training in biological engineering, cancer biology and management, and experience spanning venture capital and drug development.

She has led Bicara since 2018, taking it public in 2024. The company, focused on bi-specific antibody therapies for cancer, now has a market capitalisation of over $1.6 billion. Biocon retains a minority stake following the listing.

The succession planning comes alongside a broader restructuring at Biocon, including the merger of its generics and biologics businesses, simplification of its corporate structure and debt reduction.

The company is doubling down on biosimilars, which account for about 60% of revenue, with a portfolio of marketed products and a pipeline under development.

As part of the leadership transition, Shreehas Tambe took over as chief executive and managing director of the merged entity from April 1.

At group firm Syngene International, Siddharth Mittal will assume the role of managing director and chief executive from July 1, succeeding Peter Bains.